Stellenwert der Immuntherapie in der perioperativen Behandlung des lokalisierten muskelinvasiven Harnblasenkarzinoms

por Lewerich, J., Schmid, S. C., Gschwend, J. E., Retz, M.
Publicado 2022

Qualitätssicherung zur Therapie des muskelinvasiven und metastasierten Harnblasenkarzinoms in Deutschland: Eine Initiative der Arbeitsgemeinschaften Urologische Onkologie (AUO) und...

por Ohlmann, C. H., Kerkmann, M., Holtmann, L., Gschwend, J. E., Retz, M., de Wit, M.
Publicado 2022

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy

por Sathe, A, Guerth, F, Cronauer, M V, Heck, M M, Thalgott, M, Gschwend, J E, Retz, M, Nawroth, R
Publicado 2014

Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer

por Kuefer, R, Hofer, M D, Altug, V, Zorn, C, Genze, F, Kunzi-Rapp, K, Hautmann, R E, Gschwend, J E
Publicado 2004

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma

por Erlmeier, F., Seitz, A.K., Hatzichristodoulou, G., Stecher, L., Retz, M., Gschwend, J.E., Weichert, W., Kübler, H.R., Horn, T.
Publicado 2016

Advances in targeted alpha therapy for prostate cancer

por De Vincentis, G, Gerritsen, W, Gschwend, J E, Hacker, M, Lewington, V, O’Sullivan, J M, Oya, M, Pacilio, M, Parker, C, Shore, N, Sartor, O
Publicado 2019

Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer

por Kuefer, R, Hofer, M D, Zorn, C S M, Engel, O, Volkmer, B G, Juarez-Brito, M A, Eggel, M, Gschwend, J E, Rubin, M A, Day, M L
Publicado 2005